![]() | |
Identifiers | |
---|---|
IUPAC name
| |
PubChem CID | |
Chemical and physical data | |
Formula | C22H28FN3O |
Molar mass | 369.484 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
TRV734 is a drug developed by Trevena Inc which acts as a biased agonist at the μ-opioid receptor, selective for activation of the G-protein signalling pathway over β-arrestin 2 recruitment. It is closely related to oliceridine and has a similar pharmacological profile, but unlike oliceridine which has to be injected, TRV734 is suitable to be administered orally.
![]() | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |